Valuation: Erasca, Inc.

Market Cap 6.06B 5.3B 4.9B 4.53B 8.52B 582B 8.68B 58.42B 22.92B 285B 22.78B 22.28B 982B P/E 2026 *
-20.4x
P/E 2027 * -34.7x
Enterprise Value 5.58B 4.88B 4.51B 4.17B 7.85B 536B 7.99B 53.8B 21.11B 263B 20.98B 20.51B 904B EV / Sales 2026 *
-
EV / Sales 2027 * 10,896x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day+4.10%
1 week+6.62%
Current month+9.83%
1 month+39.43%
3 months+10.55%
6 months+110.46%
Current year+440.86%
1 week 17.63
Extreme 17.632
20.24
1 month 13.32
Extreme 13.325
20.24
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+3.92%+6.62%+1,326.95%+676.83% 6.06B
-0.19%+1.64%+3.34%+7.61% 50.35B
-0.52%-4.09%+381.35%+583.95% 39.32B
+1.10%+3.36%+33.58%-4.85% 34.69B
+2.03%+3.57%+15.93%+57.99% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
+0.13%-4.26% - - 16.49B
-0.08%+0.62%+71.17%+116.40% 15.31B
+1.36%+4.38%+16.12%+19.17% 13.8B
+0.42%+2.08%+16.02%-31.07% 12.87B
Average +0.74%-0.12%+207.44%+161.25% 24.96B
Weighted average by Cap. +0.44%-0.56%+113.70%+135.47%

Financials

2026 *2027 *
Net sales - 500K 437K 404K 373K 703K 48.03M 716K 4.82M 1.89M 23.52M 1.88M 1.84M 80.98M
Net income -299M -261M -241M -223M -420M -28.68B -427M -2.88B -1.13B -14.04B -1.12B -1.1B -48.35B -189M -165M -153M -141M -266M -18.19B -271M -1.82B -716M -8.91B -711M -696M -30.67B
Net Debt -480M -419M -388M -358M -675M -46.1B -687M -4.62B -1.81B -22.58B -1.8B -1.76B -77.73B -616M -538M -498M -460M -866M -59.18B -882M -5.94B -2.33B -28.98B -2.31B -2.26B -99.78B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
15/07/26 $20.06 +2.87% 1,704,168
14/07/26 $19.50 +8.94% 10,704,537
13/07/26 $17.90 -3.40% 2,555,112
10/07/26 $18.53 -3.39% 3,018,656
09/07/26 $19.18 +1.64% 4,199,946
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.50USD
Average target price
21.90USD
Spread / Average Target
+12.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock